Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder

Next Previous
Trial Profile

Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apimostinel (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Naurex

Most Recent Events

  • 22 Jun 2015 According to a Naurex Inc. media release, the results of this trial will be presented at the 55th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).
  • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 12 May 2015 According to Naurex media release, the data from this trial will be presented at 70th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), held at the Fairmont Royal York Hotel in Toronto.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top